Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of DWP16001 with DWC202001 and DWC202002 in Healthy Males
NCT04343547Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of DWP16001, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUClast) of DWP16001 and 2 more. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04343547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343547.